West Pharmaceutical Services is forecast to grow earnings and revenue by 10.2% and 6.3% per annum respectively. EPS is expected to grow by 10.3% per annum. Return on equity is forecast to be 18.5% in 3 years.
Key information
10.2%
Earnings growth rate
10.29%
EPS growth rate
Life Sciences earnings growth
20.5%
Revenue growth rate
6.3%
Future return on equity
18.54%
Analyst coverage
Good
Last updated
09 Jul 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
BIT:1WST - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
3,784
755
574
863
7
12/31/2027
3,537
686
513
787
14
12/31/2026
3,333
605
446
726
14
3/31/2026
3,221
543
458
715
N/A
12/31/2025
3,074
494
469
755
N/A
9/30/2025
3,018
492
379
694
N/A
6/30/2025
2,960
488
344
677
N/A
3/31/2025
2,896
467
307
665
N/A
12/31/2024
2,893
493
276
653
N/A
9/30/2024
2,876
500
322
702
N/A
6/30/2024
2,877
525
357
752
N/A
3/31/2024
2,929
569
386
757
N/A
12/31/2023
2,950
593
415
777
N/A
9/30/2023
2,927
559
420
768
N/A
6/30/2023
2,866
519
397
707
N/A
3/31/2023
2,884
552
410
711
N/A
12/31/2022
2,887
586
439
724
N/A
9/30/2022
2,909
631
388
654
N/A
6/30/2022
2,929
686
402
675
N/A
3/31/2022
2,881
684
382
647
N/A
12/31/2021
2,832
662
331
584
N/A
9/30/2021
2,681
613
341
572
N/A
6/30/2021
2,523
519
287
500
N/A
3/31/2021
2,326
423
307
504
N/A
12/31/2020
2,147
346
298
473
N/A
9/30/2020
2,037
312
272
430
N/A
6/30/2020
1,945
286
277
420
N/A
3/31/2020
1,888
261
247
377
N/A
12/31/2019
1,840
242
N/A
367
N/A
9/30/2019
1,792
230
N/A
334
N/A
6/30/2019
1,767
229
N/A
314
N/A
3/31/2019
1,745
219
N/A
291
N/A
12/31/2018
1,717
207
N/A
289
N/A
9/30/2018
1,711
155
N/A
297
N/A
6/30/2018
1,677
151
N/A
284
N/A
3/31/2018
1,627
133
N/A
288
N/A
12/31/2017
1,599
151
N/A
263
N/A
9/30/2017
1,566
190
N/A
254
N/A
6/30/2017
1,544
176
N/A
246
N/A
3/31/2017
1,535
182
N/A
237
N/A
12/31/2016
1,509
144
N/A
219
N/A
9/30/2016
1,487
138
N/A
216
N/A
6/30/2016
1,454
102
N/A
216
N/A
3/31/2016
1,426
85
N/A
217
N/A
12/31/2015
1,400
96
N/A
212
N/A
9/30/2015
1,390
94
N/A
190
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1WST's forecast earnings growth (10.2% per year) is above the savings rate (3.3%).
Earnings vs Market: 1WST's earnings (10.2% per year) are forecast to grow slower than the Italian market (10.9% per year).
High Growth Earnings: 1WST's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1WST's revenue (6.3% per year) is forecast to grow faster than the Italian market (5.9% per year).
High Growth Revenue: 1WST's revenue (6.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1WST's Return on Equity is forecast to be low in 3 years time (18.5%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/09 17:55
End of Day Share Price
2026/07/09 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
West Pharmaceutical Services, Inc. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.